$APLM

Monday’s insider activity: Major buys at Cardinal, Apollomics

Investing.com reports U.S. insider trades disclosed Monday. Apollomics (APLM) saw CEO Hung-Wen Chen buy about $7.55M and CFO Peter Lin buy $400k. Cardinal Infrastructure (CDNL) had multiple buys totaling about $6.48M. Dyne (DYN), Butterfly Network (BFLY), Kinetik (KNTK), and PBF Energy (PBF) reported large sales.

Original reporting
Published Aug 18, 2026, 1:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 1:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$APLM
Bullish
medium confidence
Mentioned
$APLM · $CDNL · $DYN · $BFLY · $KNTK · $PBF
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$APLMBullishLow
01

Why it matters

For traders, the actionable signal is mainly sentiment and near-term positioning around recent weakness (buys) or profit-taking (sells). It does not introduce new earnings, guidance, contracts, or regulatory outcomes.

02

Market read

This is a sentiment/positioning read-through from insider activity, not a fundamental catalyst report.

03

What to watch

The article lacks follow-on details such as lockups, future financing plans, or whether the private placements change ownership/control, which limits conviction on price direction.

Relevance 4/10Novelty 4/10Timing: insider transactions disclosed for Monday, with trades dated Aug. 13-14, 2026

Background

The piece is a multi-company roundup of insider trading disclosed on Monday, citing specific Form 6-K/transaction details and 10b5-1 mechanics.

Company-level read

Ticker impact

$APLMBullishMedium confidence
Context

CEO Hung-Wen Chen and CFO Peter Lin bought APLM shares in private placements on Aug. 14, 2026, at $12-$15 and $15, respectively.

Expected impact

Mild positive bias for the next few sessions, with follow-through dependent on broader biotech tape.

Evidence & confidence

The article provides specific insider purchase dates, prices, and private-placement linkage, but no new operational or financial guidance.

$CDNLBullishMedium confidence
Context

CDNL saw multiple insider buys on Aug. 14, 2026, including CEO Jeremy Simmons Spivey and directors Anthony Wood and Richard Lee, while the stock fell ~35% over the prior week.

Expected impact

Potential short-term stabilization or bounce, especially if the market continues to reward insider activity.

Evidence & confidence

The text includes transaction sizes, price ranges, and the context of a steep weekly decline, but does not disclose new earnings, contracts, or guidance.

$DYNBearishLow confidence
Context

DYN director Jason Rhodes sold about $65.2M of stock via a 10b5-1 plan on Aug. 13-14, 2026, near the stock’s ~$27.30 52-week high.

Expected impact

Slight negative bias for near-term trading, particularly if selling continues or buyers fade.

Evidence & confidence

The article is detailed on the sale mechanics and timing, but 10b5-1 plans often reduce interpretability as a directional signal.

$BFLYBearishLow confidence
Context

BFLY director Larry Robbins reported sales totaling about $20.6M between Aug. 13-17, 2026, after the stock surged ~526% over the past year.

Expected impact

Near-term upside may be capped; downside risk increases if momentum traders step aside.

Evidence & confidence

The article provides sale totals and price ranges, but no new company-specific fundamentals or guidance changes.

$KNTKBearishLow confidence
Context

KNTK director and 10% owner ISQ Global Fund II GP LLC sold ~360,337 shares for about $18.96M on Aug. 13-17, 2026, near the ~$54.12 52-week high.

Expected impact

Mild negative drift possible over days to weeks if liquidity tightens or buyers pause.

Evidence & confidence

The transaction details are clear, but insider sales are not the same as a new business development.

$PBFBearishLow confidence
Context

PBF saw a 10% owner director sell 216,356 shares for about $15.63M on Aug. 13-14, 2026, and another director sell about $12.3M after option exercise.

Expected impact

Slight negative bias, with potential for choppy trading if the market had been expecting continued upside momentum.

Evidence & confidence

The article includes sale sizes and timing, but provides no new operational or regulatory catalyst.

Market effects

Biotech and infrastructure/energy names show divergent insider behavior, but the article does not provide sector-wide fundamentals.

Primarily US-listed equities; no cross-market macro linkage is provided.

Limited, as the disclosures are company-specific insider transactions without global policy or supply-chain shocks.

Counterpoint

Insider sales can be routine (10b5-1 plans, option exercises) and insider buys can reflect diversification or private-placement mechanics rather than a new fundamental outlook.

Key entities

  • Apollomics Inc.

    CEO and CFO purchased shares in private placements on Aug. 14, 2026.

  • Cardinal Infrastructure Group Inc.

    CEO and directors bought shares on Aug. 14, 2026 amid a sharp weekly decline.

  • Dyne Therapeutics, Inc.

    Director sold shares via a 10b5-1 plan on Aug. 13-14, 2026.

  • Butterfly Network, Inc.

    Director reported sales totaling about $20.6M between Aug. 13-17, 2026.

  • Kinetik Holdings Inc.

    10% owner director sold about $18.96M of shares between Aug. 13-17, 2026.

Related articles

$DYNMedAI 8/10

Why Dyne Therapeutics (DYN) Is Back In The Spotlight

Dyne Therapeutics (DYN) reported 1-year efficacy and safety data from its Phase 1/2 ACHIEVE trial, showing functional gains in myotonic dystrophy type 1. The stock has fallen 37% in 3 months but is up 84% over 3 years. Analysts suggest it's 57% undervalued at $36 per share, citing its FORCE platform's efficiency. Risks include potential trial failures and equity dilution.

$PBFMed

BMO reiterates PBF Energy stock rating on strong Q3 outlook

BMO Capital reiterated a Market Perform rating on PBF Energy (NYSE:PBF) with an $80 price target. The company's stock is near its 52-week high, reflecting an 189% year-to-date gain. BMO revised its Q3 2026 earnings estimate to $11.99 per share, citing strong operational performance and high indicators. PBF Energy plans to use excess cash flow for improvements and may raise its dividend, currently at 1.43%.

$DYNHighAI 8/10

Dyne Therapeutics stock rises on positive DM1 trial results

Dyne Therapeutics (DYN) shares rose 2.1% after reporting 1-year trial data for DM1 treatment z-basivarsen. The Phase 1/2 ACHIEVE trial showed improvements in functional tests and muscle strength. The company expects topline data in Q1 2027, aiming for U.S. Accelerated Approval submission in Q3 2027. Z-basivarsen showed a favorable safety profile.